Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of cevostamab in patients with relapsed or refractory multiple myeloma previously exposed to B-lymphocyte maturation antigen-targeted therapy.
THE AIM OF THIS STUDY IS TO DETERMINE THE EFFECTS, GOOD OR BAD, OF CEVOSTAMAB IN PARTICIPANTS WITH MULTIPLE MYELOMA THAT HAS WORSENED OR NOT RESPONDED TO TREATMENT.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA PREVIOUSLY EXPOSED TO B-LYMPHOCYTE MATURATION ANTIGEN-TARGETED THERAPY. IMMUNOTHERAPY.
- Code EudraCT: 2021-006816-10
- Protocol number: CO43476
- Promoter: Roche Farma, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.